Free Trial
NASDAQ:BLTE

Belite Bio (BLTE) Stock Price, News & Analysis

Belite Bio logo
$61.63 +0.63 (+1.03%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$61.46 -0.17 (-0.28%)
As of 05/27/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Belite Bio Stock (NASDAQ:BLTE)

Key Stats

Today's Range
$60.23
$61.82
50-Day Range
$54.10
$67.29
52-Week Range
$43.70
$86.53
Volume
25,209 shs
Average Volume
49,682 shs
Market Capitalization
$1.96 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$96.67
Consensus Rating
Buy

Company Overview

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Belite Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

BLTE MarketRank™: 

Belite Bio scored higher than 41% of companies evaluated by MarketBeat, and ranked 644th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Belite Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Belite Bio has only been the subject of 3 research reports in the past 90 days.

  • Read more about Belite Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Belite Bio are expected to grow in the coming year, from ($1.17) to ($0.83) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Belite Bio is -55.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Belite Bio is -55.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Belite Bio has a P/B Ratio of 18.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Belite Bio's valuation and earnings.
  • Percentage of Shares Shorted

    0.23% of the outstanding shares of Belite Bio have been sold short.
  • Short Interest Ratio / Days to Cover

    Belite Bio has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Belite Bio has recently increased by 20.10%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Belite Bio does not currently pay a dividend.

  • Dividend Growth

    Belite Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.23% of the outstanding shares of Belite Bio have been sold short.
  • Short Interest Ratio / Days to Cover

    Belite Bio has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Belite Bio has recently increased by 20.10%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Belite Bio has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Belite Bio this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Belite Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 0.53% of the stock of Belite Bio is held by institutions.

  • Read more about Belite Bio's insider trading history.
Receive BLTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter.

BLTE Stock News Headlines

3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
See More Headlines

BLTE Stock Analysis - Frequently Asked Questions

Belite Bio's stock was trading at $63.10 at the beginning of 2025. Since then, BLTE stock has decreased by 2.3% and is now trading at $61.63.
View the best growth stocks for 2025 here
.

Belite Bio, Inc (NASDAQ:BLTE) announced its quarterly earnings data on Monday, March, 17th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.02.
Read the conference call transcript
.

Belite Bio (BLTE) raised $36 million in an initial public offering (IPO) on Friday, April 29th 2022. The company issued 6,000,000 shares at $5.50-$6.50 per share.

Belite Bio's top institutional investors include GAMMA Investing LLC (0.38%), Alyeska Investment Group L.P. (0.26%) and GAMMA Investing LLC (0.01%).

Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Belite Bio investors own include Paycom Software (PAYC), Centrus Energy (LEU), Planet Labs PBC (PL), uniQure (QURE), Grayscale Ethereum Trust (ETH) (ETHE), Marathon Oil (MRO) and Vale (VALE).

Company Calendar

Last Earnings
3/17/2025
Today
5/28/2025
Next Earnings (Estimated)
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BLTE
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$96.67
High Stock Price Target
$110.00
Low Stock Price Target
$80.00
Potential Upside/Downside
+56.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$31.63 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.28 per share
Price / Book
18.79

Miscellaneous

Free Float
27,607,000
Market Cap
$1.96 billion
Optionable
Not Optionable
Beta
-1.48
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:BLTE) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners